SCHEDULE: Commodore Capital Discloses 9.9% Stake in Perspective Therapeutics

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in Perspective Therapeutics, Inc., including shares from pre-funded warrants.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 11,939,753 shares of Perspective Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of the company's outstanding common stock.
• The stake comprises 6,336,782 shares of common stock and 5,602,971 shares acquirable through the exercise of pre-funded warrants.
• The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%, which excludes 995,075 shares from the reported beneficial ownership.
• The ownership percentage is calculated based on 113,914,078 shares outstanding as of February 3, 2026, plus the 5,602,971 shares from exercisable warrants.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by an institutional investor like Commodore Capital can be interpreted as a vote of confidence in Perspective Therapeutics, potentially signaling future growth or value.

Positives

• A significant institutional investor, Commodore Capital, has taken a substantial 9.9% stake in Perspective Therapeutics, indicating confidence in the company's future prospects.
• The investment includes pre-funded warrants, suggesting a long-term strategic interest and potentially providing future capital to the company upon exercise.

Negatives

• The beneficial ownership limitation of 9.99% on the pre-funded warrants means a portion of potential shares (995,075 shares) is currently excluded from the reported beneficial ownership, limiting immediate upside from full warrant exercise for the reporting persons.

Risks

• The beneficial ownership limitation on the pre-funded warrants could restrict the reporting persons from immediately increasing their stake beyond 9.99% through warrant exercise, potentially impacting their influence or investment strategy.
• While the filing states the investment is not for control, the mention of 'activities solely in connection with a nomination under 240.14a-11' suggests a potential for future engagement in corporate governance, which could lead to management or board changes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a significant stake taken by an investment manager like Commodore Capital in a therapeutics company often signals a belief in the company's long-term potential, particularly in sectors like biotechnology where development cycles are long and capital intensive. Such disclosures can attract attention from other institutional investors, potentially validating the company's strategic direction or pipeline.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could be viewed positively, potentially increasing investor confidence and attracting further investment. It also introduces a large, potentially active, shareholder.
• Company Management: Management will need to consider the implications of a 9.9% shareholder, especially given the mention of potential Rule 240.14a-11 activities.

Next Steps

• The reporting persons may exercise their pre-funded warrants to acquire additional shares, up to the 9.99% beneficial ownership limitation.
• The reporting persons may engage in activities solely in connection with a nomination under Rule 240.14a-11, indicating potential future involvement in corporate governance.

Key Dates

Recommendation

The disclosure of a significant 9.9% stake by an institutional investor like Commodore Capital is generally a positive signal, indicating a belief in the company's value. However, a Schedule 13G is a passive filing, and while it suggests confidence, it doesn't provide new operational or financial performance data to warrant a 'buy' recommendation. The mention of potential Rule 240.14a-11 activities suggests a watchful 'hold' stance, as future actions by this significant shareholder could influence the company's direction and valuation. Investors should monitor future filings and company performance for further catalysts.

Keywords

Perspective Therapeutics, Commodore Capital, Beneficial Ownership, Schedule 13G, Common Stock, Pre-funded Warrants, Institutional Investor, Investment Management, Shareholder Stake